Xilio Therapeutics, Inc.: investing cash flow
Investing cash flow for Xilio Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Xilio Therapeutics, Inc. financial histories
What this measure means
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
Exact concept: us-gaap:NetCashProvidedByUsedInInvestingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -518,000 | USD | 2026-03-23 | 10-K · 0001193125-26-118550 |
| 2024-01-01 | 2024-12-31 | -36,000 | USD | 2026-03-23 | 10-K · 0001193125-26-118550 |
| 2023-01-01 | 2023-12-31 | -486,000 | USD | 2025-03-11 | 10-K · 0001558370-25-002640 |
| 2022-01-01 | 2022-12-31 | -1,867,000 | USD | 2024-04-01 | 10-K · 0001558370-24-004530 |
| 2021-01-01 | 2021-12-31 | -1,100,000 | USD | 2023-03-02 | 10-K · 0001558370-23-002687 |
| 2020-01-01 | 2020-12-31 | -2,188,000 | USD | 2022-03-01 | 10-K · 0001558370-22-002552 |
Related financial histories
- Xilio Therapeutics, Inc.: total assets
- Xilio Therapeutics, Inc.: total liabilities
- Xilio Therapeutics, Inc.: stockholders equity
- Xilio Therapeutics, Inc.: cash and cash equivalents
- Xilio Therapeutics, Inc.: net income or loss
- Xilio Therapeutics, Inc.: operating cash flow
- Xilio Therapeutics, Inc.: capital expenditure payments
- Xilio Therapeutics, Inc.: financing cash flow
- Xilio Therapeutics, Inc.: retained earnings or deficit
- Xilio Therapeutics, Inc.: basic weighted-average shares
- Xilio Therapeutics, Inc.: basic earnings per share
- Xilio Therapeutics, Inc.: diluted earnings per share
- Xilio Therapeutics, Inc.: net property, plant and equipment
- Xilio Therapeutics, Inc.: share-based compensation expense
- Xilio Therapeutics, Inc.: operating income or loss
- Xilio Therapeutics, Inc.: current assets
- Xilio Therapeutics, Inc.: current liabilities
- Xilio Therapeutics, Inc.: current accounts payable
- Xilio Therapeutics, Inc.: operating expenses
- Xilio Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Xilio Therapeutics, Inc. / CIK 0001840233
- Captured
- 2026-09-21T17:30:01.125Z
- SEC response SHA-256
b9926482eefa7db7b34c666b313bfea22c6dec41b8b13a61f284b5e4d27a2eaa
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001840233.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))